Clinical trial
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment (EAE116)
NCT05147493 is registered in ClinicalTrials.gov with Hellenic Society of Hematology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment (EAE116)
- Lead sponsor
- Hellenic Society of Hematology
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 30, 2022
- Completion date
- February 28, 2025
- Enrollment
- 51 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.